{"id":745765,"date":"2018-02-13T16:30:00","date_gmt":"2018-02-13T16:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/"},"modified":"2025-11-07T01:27:29","modified_gmt":"2025-11-07T06:27:29","slug":"merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/","title":{"rendered":"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that it will be stopping protocol 019, also known as the<br \/>\n      APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an<br \/>\n      investigational small molecule inhibitor of the beta-site amyloid<br \/>\n      precursor protein cleaving enzyme 1 (BACE1), in people with prodromal<br \/>\n      Alzheimer\u2019s disease (AD). The decision to stop the study follows a<br \/>\n      recommendation by the external Data Monitoring Committee (eDMC), which<br \/>\n      assessed overall benefit\/risk during a recent interim safety analysis.<br \/>\n      The eDMC concluded that it was unlikely that positive benefit\/risk could<br \/>\n      be established if the trial continued.<b> <\/b>Data from the APECS study<br \/>\n      will be presented at an upcoming medical meeting.\n    <\/p>\n<p>\n      \u201cWe are disappointed with this outcome, especially given the lack of<br \/>\n      treatment options for patients suffering from Alzheimer\u2019s disease,\u201d said<br \/>\n      Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe are<br \/>\n      grateful to the patients and caregivers who participated in this study,<br \/>\n      and despite this outcome, Merck remains committed to developing novel<br \/>\n      therapies for the treatment of Alzheimer\u2019s and other neurodegenerative<br \/>\n      diseases.\u201d\n    <\/p>\n<p>\n      <b>About the APECS Study<\/b><br \/>\n<br \/>APECS is a randomized,<br \/>\n      placebo-controlled, parallel-group, double-blind Phase 3 clinical trial<br \/>\n      evaluating the efficacy and safety of verubecestat in people with<br \/>\n      prodromal AD. Subjects are randomized to receive placebo, or 12 mg or 40<br \/>\n      mg verubecestat, once-daily. The primary efficacy outcome of the study<br \/>\n      is change from baseline in the Clinical Dementia Rating Scale-Sum of<br \/>\n      Boxes (CDR-SB) score following 104 weeks of treatment. For further<br \/>\n      information please see NCT01953601 at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=97bf0bd483e216e8bc44097bafb131a0\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world\u2019s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=ba00afd96194c66f7e077772e6a51377\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ab55477213fb289001d530a25e9e72bc\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=5303dfe6cb819af0dc0263b1c523608a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=7c5e487a5c27d93ff815aa596a434d51\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=b280a6a0223fcb1b75cb3627182c12bd\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck%2F&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=a971d288326bf82e11c5c1f339625451\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__www.sec.gov_%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DO8jhEp-nT1TSdpa_yG56i7hRJDQokNmq3YfxukY44g8%26s%3D1ESN_N5lMWF-y_13JQLzDA2UvkeYb6CupBRpqAptuiU%26e%3D&amp;esheet=51758339&amp;newsitemid=20180213006582&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=c3956cbcea65ad661115fc138a121b53\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180213006582r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Ian        McConnell, 908-740-1921<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer\u2019s disease (AD). The decision to stop the study follows a recommendation by the external Data Monitoring Committee (eDMC), which assessed overall benefit\/risk during a recent interim safety analysis. The eDMC concluded that it was unlikely that positive benefit\/risk could be established if the trial continued. Data from the APECS study will be presented at an upcoming medical meeting. \u201cWe are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer\u2019s disease,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe are grateful to the patients and caregivers<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745765","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer\u2019s disease (AD). The decision to stop the study follows a recommendation by the external Data Monitoring Committee (eDMC), which assessed overall benefit\/risk during a recent interim safety analysis. The eDMC concluded that it was unlikely that positive benefit\/risk could be established if the trial continued. Data from the APECS study will be presented at an upcoming medical meeting. \u201cWe are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer\u2019s disease,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe are grateful to the patients and caregivers\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\\\/\",\"name\":\"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-02-13T16:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer\u2019s disease (AD). The decision to stop the study follows a recommendation by the external Data Monitoring Committee (eDMC), which assessed overall benefit\/risk during a recent interim safety analysis. The eDMC concluded that it was unlikely that positive benefit\/risk could be established if the trial continued. Data from the APECS study will be presented at an upcoming medical meeting. \u201cWe are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer\u2019s disease,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe are grateful to the patients and caregivers","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:29+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/","name":"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-02-13T16:30:00+00:00","dateModified":"2025-11-07T06:27:29+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f0dfe953-ee13-473b-afa1-d4380064b66a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745765\/revisions"}],"predecessor-version":[{"id":3675122,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745765\/revisions\/3675122"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745765"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}